DIC in obstetric hemorrhage: recognition and management priorities?

DIC in obstetric hemorrhage: recognition and management priorities?

• A. Prolonged bleeding with abnormal coag tests; treat underlying cause, transfuse platelets and FFP as needed, provide hemodynamic support.
• B. Antifibrinolytics alone.
• C. Ignore coagulopathy if bleeding persists.
• D. Transfuse red cells only.

Answer: (A)

In obstetric DIC, the main concept is a consumption coagulopathy where widespread activation of clotting leads to depletion of platelets and coagulation factors, producing ongoing bleeding even as thrombosis can occur. Recognizing this hinges on both the clinical picture of heavy, uncontrollable bleeding in the setting of an obstetric hemorrhage and laboratory signs of coagulopathy: low platelets, prolonged PT/aPTT, low fibrinogen, and elevated D-dimer. The best management approach combines stopping or addressing the trigger and immediately correcting the coagulopathy while maintaining circulation. This means treating the underlying obstetric cause (for example, abruptio placentae, retained products, or massive hemorrhage) and supporting the patient with a balanced transfusion strategy: give platelets when counts are low or there is active bleeding, provide fresh frozen plasma to replace depleted clotting factors, and use cryoprecipitate or fibrinogen concentrate if fibrinogen is low. In many settings, this is guided by a massive transfusion protocol that aims to restore a practical balance of red cells, plasma, and platelets to control bleeding and maintain perfusion. Throughout, aggressive hemodynamic support with appropriate fluids and vasopressors as needed is crucial, and labs should be rechecked frequently to guide ongoing therapy. Why the other approaches don’t fit: using antifibrinolytics alone does not correct the underlying depletion of platelets and factors and may not control ongoing bleeding in DIC; ignoring the coagulopathy is dangerous and allows hemorrhage and organ failure to progress; transfusing red cells alone addresses oxygen delivery but does not fix the coagulation deficit, risking continued bleeding.

In obstetric DIC, the main concept is a consumption coagulopathy where widespread activation of clotting leads to depletion of platelets and coagulation factors, producing ongoing bleeding even as thrombosis can occur. Recognizing this hinges on both the clinical picture of heavy, uncontrollable bleeding in the setting of an obstetric hemorrhage and laboratory signs of coagulopathy: low platelets, prolonged PT/aPTT, low fibrinogen, and elevated D-dimer.

The best management approach combines stopping or addressing the trigger and immediately correcting the coagulopathy while maintaining circulation. This means treating the underlying obstetric cause (for example, abruptio placentae, retained products, or massive hemorrhage) and supporting the patient with a balanced transfusion strategy: give platelets when counts are low or there is active bleeding, provide fresh frozen plasma to replace depleted clotting factors, and use cryoprecipitate or fibrinogen concentrate if fibrinogen is low. In many settings, this is guided by a massive transfusion protocol that aims to restore a practical balance of red cells, plasma, and platelets to control bleeding and maintain perfusion. Throughout, aggressive hemodynamic support with appropriate fluids and vasopressors as needed is crucial, and labs should be rechecked frequently to guide ongoing therapy.

Why the other approaches don’t fit: using antifibrinolytics alone does not correct the underlying depletion of platelets and factors and may not control ongoing bleeding in DIC; ignoring the coagulopathy is dangerous and allows hemorrhage and organ failure to progress; transfusing red cells alone addresses oxygen delivery but does not fix the coagulation deficit, risking continued bleeding.